P2773 Value of an electrophysiologic study before the implantation of a biventricular pacemaker in patients with chronic heart failure and no history of ventricular arrhythmias

2003 ◽  
Vol 24 (5) ◽  
pp. 520
Author(s):  
K SEIDL
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Ventricular Arrhythmias ◽  
Electrophysiologic Study ◽  
Biventricular Pacemaker ◽  
History Of

scholarly journals Effect of frailty on treatment, hospitalisation and death in patients with chronic heart failure

2021 ◽  
Author(s):  
S. Sze ◽  
P. Pellicori ◽  
J. Zhang ◽  
J. Weston ◽  
I. B. Squire ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Clinical Frailty Scale ◽  
Mineralocorticoid Receptor Antagonist ◽  
Reduced Ejection Fraction ◽  
Frail Patients ◽  
History Of ◽  
Poor Outcomes ◽  
To Receive

Abstract Background Frailty is common in patients with chronic heart failure (CHF) and is associated with poor outcomes. The natural history of frail patients with CHF is unknown. Methods Frailty was assessed using the clinical frailty scale (CFS) in 467 consecutive patients with CHF (67% male, median age 76 years, median NT-proBNP 1156 ng/L) attending a routine follow-up visit. Those with CFS > 4 were classified as frail. We investigated the relation between frailty and treatments, hospitalisation and death in patients with CHF. Results 206 patients (44%) were frail. Of 291 patients with HF with reduced ejection fraction (HeFREF), those who were frail (N = 117; 40%) were less likely to receive optimal treatment, with many not receiving a renin–angiotensin–aldosterone system inhibitor (frail: 25% vs. non-frail: 4%), a beta-blocker (16% vs. 8%) or a mineralocorticoid receptor antagonist (50% vs 41%). By 1 year, there were 56 deaths and 322 hospitalisations, of which 25 (45%) and 198 (61%), respectively, were due to non-cardiovascular (non-CV) causes. Most deaths (N = 46, 82%) and hospitalisations (N = 215, 67%) occurred in frail patients. Amongst frail patients, 43% of deaths and 64% of hospitalisations were for non-CV causes; 58% of cardiovascular (CV) deaths were due to advancing HF. Among non-frail patients, 50% of deaths and 57% of hospitalisations were for non-CV causes; all CV deaths were due to advancing HF. Conclusion Frailty in patients with HeFREF is associated with sub-optimal medical treatment. Frail patients are more likely to die or be admitted to hospital, but whether frail or not, many events are non-CV. Graphical abstract

Emerging Therapies for Acute and Chronic Heart Failure

2016 ◽  
Vol 29 (1) ◽  
pp. 46-57 ◽  
Author(s):  
Sarah Hanigan ◽  
Robert J. DiDomenico
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cardiovascular Death ◽  
Phase 3 ◽  
Reduced Ejection Fraction ◽  
Emerging Therapies ◽  
Treat Heart Failure ◽  
Novel Drugs ◽  
The Us ◽  
History Of

Although the period from 1953 to 2001 resulted in the approval of more than 30 medications currently used to treat heart failure (HF), few novel drugs have been approved in the last decade. However, the investigational pipeline for HF medications once again appears promising. In patients with chronic heart failure with reduced ejection fraction (HFrEF), ivabradine and valsartan/sucubitril (LCZ696) were recently approved by the US Food and Drug Administration. Both agents have been shown to reduce the risk of cardiovascular death and HF hospitalization. In the treatment of acute HF, serelaxin and ularitide are the farthest along in development. Both agents have demonstrated favorable effects on surrogate end points and preliminary data suggest a possible mortality benefit with serelaxin. Consequently, phase 3 trials are ongoing to evaluate the effect of serelaxin and ularitide on clinical outcomes. Given the poor history of recent investigational acute HF drugs that have advanced to phase 3/4 studies, enthusiasm for both serelaxin and ularitide must be tempered until these trials are completed.

Problems arising when a system of automated weight monitoring is introduced into the home as part of the care for patients with chronic heart failure

2007 ◽  
Vol 13 (1_suppl) ◽  
pp. 29-31 ◽  
Author(s):  
Glenis Johnston ◽  
Gwyneth Weatherburn ◽  
Stephen Ward ◽  
Julie Hendry
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Monitoring System ◽  
Thematic Analysis ◽  
Electronic Monitoring ◽  
Call Centre ◽  
Telemedicine System ◽  
Telemedicine Service ◽  
History Of ◽  
Weight Monitoring

Patients with a history of chronic heart failure participated in a study to evaluate a home telemedicine system which monitored their weight daily. Within three weeks of beginning the study, interviews were conducted with patients (n = 5), their partners (n = 4) and their heart failure nurses (n = 3). A thematic analysis was carried out in order to probe their experiences of the illness and their perception of how telemedicine might affect those experiences. When asked, the participants and their partners did not consider that the electronic monitoring system would be much use to them. Nurses also had a number of misconceptions about the telemedicine service. The results demonstrated that patients needed better education, both in the management of their condition and in the use of the telemedicine equipment and the service provided by the call centre, before the telemedicine system could fulfil its potential.

Common RyR2 variants associate with ventricular arrhythmias and sudden cardiac death in chronic heart failure

2010 ◽  
Vol 119 (5) ◽  
pp. 215-226 ◽  
Author(s):  
Yuqin Ran ◽  
Jingzhou Chen ◽  
Ning Li ◽  
Weili Zhang ◽  
Li Feng ◽  
...  
Keyword(s):  
Heart Failure ◽  
Sudden Cardiac Death ◽  
Chronic Heart Failure ◽  
Cardiac Death ◽  
Ventricular Arrhythmias ◽  
Protective Factor ◽  
Critical Role ◽  
Functional Variants ◽  
Increased Risk ◽  
Genes Encoding

Ca2+ cycling plays a critical role in heart failure and lethal arrhythmias. As susceptibility to sudden cardiac death is considered to be a heritable trait in general population, we have therefore investigated whether potentially functional variants of genes encoding RyR2 (ryanodine receptor 2) and the L-type Ca2+ channel are related to the risk of ventricular arrhythmias and sudden cardiac death in CHF (chronic heart failure) in a case-control study. We found that the A allele of rs3766871 in RYR2 was associated with an increased risk of ventricular arrhythmias in patients with CHF {odds ratio, 1.66 [95% CI (confidence interval), 1.21–2.26]; P=0.002}. During a median follow-up period of 32 months in 1058 (85.0%) patients, 296 (28.0%) patients died from heart failure, of whom 141 (47.6%) had sudden cardiac death. After adjustment for age, gender and suspected risk factors, patients carrying the A allele of rs3766871 had an increased risk of cardiac death {HR (hazard ratio), 1.53 [95% CI, 1.11–2.12]; P=0.010} and sudden cardiac death [HR, 1.92 (95% CI, 1.25–2.94); P=0.003]. Patients carrying the A allele of rs790896 in RYR2 had a reduced risk of sudden cardiac death [HR, 0.65 (95% CI, 0.45–0.92); P=0.015]. In conclusion, the A allele of rs3766871 in RYR2 not only associates with ventricular arrhythmias, but also serves as an independent predictor of sudden cardiac death, and the A allele of rs790896 in RYR2 is a protective factor against sudden cardiac death in patients with CHF.

scholarly journals ACUTE HEART FAILURE PATIENTS

2016 ◽  
Vol 23 (10) ◽  
pp. 1281-1287
Author(s):  
Naeem Asghar ◽  
Shakeel Ahmad ◽  
Muhammad Nazim ◽  
Hafiz Muhammad Faiq Ilyas ◽  
Muhammad Nouman Ahmad
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Acute Heart Failure ◽  
De Novo ◽  
Uncontrolled Hypertension ◽  
Diabetic Patients ◽  
Study Group ◽  
Acute Decompensation ◽  
History Of ◽  
Precipitating Factor

Objectives: The objective of the study is to identify the precipitating factorsamong the patients presenting with AHF (Acute Heart Failure). Study Design: Cross sectionalstudy. Setting: Punjab Institute of Cardiology, Lahore. Duration of Study: 6 months. From01-01-2007 to 30-06-2007. Methodology: The calculated sample size was 170 cases with 5%margin of error, 95% confidence level taking expected percentage of uncontrolled hypertensioni.e. 12% (least percentage among all precipitating factors). Results: In the study group, mostlypatients of AHF were young with mean age of 55 + 6.99 years, male (61.8%), Diabetic (53.5%)and have history of chronic Heart Failure (63.5%). In male the most common precipitating factorof AHF was ACS (39.04%) while in female uncontrolled hypertension (38.46%). Conclusion:In diabetic patients the most common precipitating factor of AHF was ACS (30.7%). In patientswith acute decompensation of chronic heart failure the most common precipitating factor wasnon-compliance of medication (30.55%) while in patients with de novo Acute Heart Failure itwas ACS (41.93%). ACS was the common precipitating factor of Acute Heart Failure (28.2%)among the study group irrespective of gender, diabetes and history of Heart Failure.

scholarly journals Beta-blockers, and real clinical practice in Russia: the gap between the understanding of the doses of beta-blockers and subsequent prognosis in patients with cardiovascular disease

2017 ◽  
Vol 14 (3) ◽  
pp. 36-41
Author(s):  
I V Fomin ◽  
D S Polyakov
Keyword(s):  
Myocardial Infarction ◽  
Heart Failure ◽  
Acute Myocardial Infarction ◽  
Chronic Heart Failure ◽  
Beta Blockers ◽  
Previous History ◽  
Clinical Manifestations ◽  
Population Level ◽  
Cardiovascular Pathology ◽  
History Of

Presents an analysis of the reception beta-blockers in three epidemiological studies sections of the EPOKhA. Respondents in each slice (2002, 2007, 2017) were stratified into 5 subgroups: only suffering from hypertension - AH (subgroup AH), patients with stable angina pectoris, but in history and clinically has no evidence of acute myocardial infarction (AMI) and chronic heart failure (subgroup of coronary heart disease); after myocardial infarction, but do not have clinical manifestations of chronic heart failure (subgroup myocardial infarction); patients with acute myocardial infarction formed for any reason, but with no previous history of AMI (subgroup chronic heart failure), and patients with clinical manifestations of chronic heart failure after suffering AMI in anamnesis (subgroup myocardial infarction + chronic heart failure). During 15 years in the Russian Federation the frequency of administration of beta-blockers increased from 20% in the section of cardiovascular pathology to 30%. The most sensitive to the use of beta-blockers were patients with a history of AMI and chronic heart failure. Prolonged beta-blockers have been used at the population level only in 2007, but the frequency with any cardiovascular pathology does not exceed the 50% threshold, and the achievement of goals (control heart rate) does not exceed 10% of the level at any pathology. This dependence is associated with low-dose beta-blockers. In any case, the dose of beta-blockers did not exceed 50% of recommended that can be a separate cause of cardiovascular mortality at the population level in Russia.

Sign in / Sign up

Export Citation Format

Share Document